Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.5K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

326
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
326
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

548
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
548
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

353
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
353

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Putting What Matters First: A Case-Based Approach to Goal Setting to Promote Older Adult Brain Health in the AgeWISE-Action Plan Program.

American journal of lifestyle medicine·2026
Same author

THE SOCIETY OF CRITICAL CARE CARDIOLOGY - RATIONALE, BLUEPRINT, AND LESSONS LEARNED IN THE CREATION OF A NEW MULTIDISCIPLINARY PROFESSIONAL ORGANIZATION.

American heart journal·2026
Same author

Pressure-Volume-Derived Ventricular Energetics Across Mechanical Circulatory Support Strategies in Cardiogenic Shock.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

Systems of Care in Cardiogenic Shock: Team-Based Management, Shock Networks, and Post Discharge Pathways.

Interventional cardiology clinics·2026
Same author

Optimal Large-Bore Vascular Access and Closure for Percutaneous Mechanical Circulatory Support in Cardiogenic Shock.

Interventional cardiology clinics·2026
Same author

Clinical Characteristics and Outcomes in Intra-aortic Balloon Pump-Supported Cardiogenic Shock Among Patients Transferred to Tertiary Care Centers.

Journal of the Society for Cardiovascular Angiography & Interventions·2026

Related Experiment Video

Updated: Jun 17, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.4K

Medical Management and Device-Based Therapies in Chronic Heart Failure.

Andrew H Nguyen1, Madelyn Hurwitz2, Jacob Abraham3

  • 1Inova Schar Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, Virginia.

Journal of the Society for Cardiovascular Angiography & Interventions
|August 12, 2024
PubMed
Summary

Guideline-directed medical therapy for heart failure (HF) has advanced, but limitations persist. Device-based interventions offer promising solutions for managing chronic HF and improving patient outcomes.

Keywords:
devicesheart failuremedical management

More Related Videos

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

13.5K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K

Related Experiment Videos

Last Updated: Jun 17, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.4K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

13.5K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K

Area of Science:

  • Cardiology
  • Medical Devices

Background:

  • Heart failure (HF) is a leading cause of global morbidity and mortality.
  • Current guideline-directed medical therapy (GDMT) offers advancements for HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF).

Purpose of the Study:

  • To review the current landscape of GDMT for chronic HF.
  • To discuss limitations and barriers to GDMT implementation.
  • To summarize device-based therapies for HF management.

Main Methods:

  • Literature review of guideline-directed medical therapy for chronic heart failure.
  • Analysis of limitations in medical therapy implementation and adherence.
  • Review of established and emerging device-based interventions for all HF phenotypes.

Main Results:

  • Despite medical advancements, significant barriers to GDMT implementation exist, including delays, tolerability, and cost.
  • A substantial number of patients remain symptomatic with poor outcomes.
  • Device-based interventions show promise and established efficacy across HF phenotypes.

Conclusions:

  • Unmet clinical needs in HF management persist despite optimal medical therapy.
  • Device-based therapies represent a growing and important area for improving outcomes in chronic heart failure.
  • A comprehensive approach integrating medical and device therapies is crucial for effective HF management.